A Urine Test Just Challenged the Most Accepted Assumption in Prostate Cancer Monitoring

For decades, the repeat biopsy has been treated as an unavoidable feature of active surveillance for low-grade prostate cancer, and that assumption has caused a measurable and largely unacknowledged amount of harm. A study just published in the Journal of Urology now offers the most clinically credible challenge to that assumption yet, and the implications extend well beyond the test itself into a broader question about what responsible prostate cancer monitoring should look like in the first place.

The test is called MPS2-AS (MyProstateScore 2.0 Active Surveillance). It is a urine test that requires no needle, no tissue sampling, and no disruption of the prostate gland. A urine sample is analyzed for molecular markers that reflect what the prostate produces at the cellular level, reading biological signals rather than physically extracting tissue to search for them. Researchers at Vanderbilt Health evaluated it across 330 men already scheduled for a surveillance biopsy at 11 urology practices across the United States, and the results are worth examining carefully.

This is one of the reasons why Dr. Petteruti, in one of Intellectual Medicine’s viral podcast, Don’t Biopsy Your Prostate Until You Hear This, insisted that biopsy should be the last option or not an option at all for most men.

What the Study Found

The test demonstrated a 99% negative predictive value for high-grade cancer, defined as Grade Group 3 or above. That figure means men who tested negative had approximately a 1 in 100 chance of harboring the kind of cancer that genuinely warrants treatment. Applied to the study cohort, the test would have eliminated roughly 64% of unnecessary biopsies, procedures performed on men who turned out not to have high-grade disease, while missing only about 3% of the higher-grade tumors that do merit clinical attention.

For context, MRI, which has become the dominant noninvasive tool in active surveillance over the past several years, missed around 18% of high-grade upgrades in the same population and avoided only approximately half of unnecessary biopsies. The urine test outperformed imaging on both measures. It also performed consistently in Black patients, a population that faces higher prostate cancer incidence and mortality and is frequently underserved by diagnostic tools validated primarily in other demographic groups.

These are not marginal improvements in diagnostic performance. A 99% negative predictive value is a number that changes clinical decisions, and a 64% reduction in unnecessary biopsies represents a meaningful reduction in procedural burden for a population that has been carrying it for decades without a better alternative.

An Intellectual Medicine podcast has shed light on the fact that there is more to MRI than meets the eye.

Why the Biopsy Treadmill Exists and What It Costs

To understand why this test is significant, it helps to understand the clinical problem it is addressing. A man diagnosed with low-grade prostate cancer and placed on active surveillance has historically faced repeat biopsies every two to three years, not because his cancer is reliably progressing but because the tools available to monitor it have not been precise enough to say with confidence that it is not. That cycle can continue for years. In some cases, it continues for decades.

Each biopsy in that sequence carries real consequences. Pain and bleeding are common. Infection risk, including the small but non-trivial risk of sepsis, accompanies every procedure. There is also the concern around capsule disruption, the physical disruption of the prostate gland’s structural integrity through repeated needle sampling, which has been underweighted in most clinical discussions about the risks of surveillance biopsy.

The deeper problem is that a biopsy samples approximately 1% of the prostate gland through needle cores placed at fixed intervals across the tissue. It cannot reliably confirm what is not present. A negative biopsy does not clear a man. It means nothing was found in the areas sampled during that particular procedure. That fundamental limitation is what drives men back onto the treadmill year after year without resolution, and it is what the molecular approach of MPS2-AS is designed to circumvent.

A Different Philosophy of Monitoring

What MPS2-AS does is read the molecular signals the prostate is actively producing, rather than physically disrupting the gland to search for cells under a microscope. It cannot visualize what cancer looks like histologically. What it can do is detect whether the gland is generating the molecular signatures of high-grade disease, and that is a different and, in many respects, more directly relevant question for a man trying to determine whether his low-grade cancer has changed.

The researchers make a point worth taking seriously. MRI identifies suspicious lesions based on their appearance and location within the gland. It cannot directly assess the molecular behavior of cancer cells. Some tumors that have upgraded to a more aggressive grade do not appear dramatically different on imaging until they have grown considerably. A test that reads molecular output from the prostate may detect those cellular changes earlier than imaging can, before structural changes are visible at all.

This is not simply a better version of an existing tool. It reflects a different underlying logic for how monitoring should work, one that prioritizes the biological activity of the disease over the physical sampling of tissue. That distinction carries implications for how active surveillance is structured, how frequently invasive procedures are scheduled, and how men experience the years of monitoring that follow a low-grade diagnosis.

The Larger Question This Test Does Not Answer

The clinical value of MPS2-AS is real, and a 99% negative predictive value is a meaningful basis for deferring a scheduled biopsy in men who test negative. That is a tool the field has not previously had, and the evidence supporting it is credible enough to warrant serious clinical consideration.

The question the study does not address is the one that sits behind the entire framework of active surveillance. The assumption embedded in surveillance monitoring is that low-grade prostate cancer requires ongoing vigilance for potential upgrading, and that upgrading, when detected, warrants intervention. The ProtecT trial, which followed over 1,500 men for 15 years, found no significant difference in prostate cancer-specific mortality between surgery, radiation, and active monitoring. That finding does not change because a better monitoring test now exists.

What it means is that the procedural burden of active surveillance, the repeated biopsies, the anxiety of recurrent testing, and the accumulated risks of each procedure have been carried by a population of men, a significant proportion of whom were unlikely to die from their cancer regardless of which management path was chosen. A test that reduces that burden is genuinely valuable. It does not, however, resolve the upstream question of how aggressively low-grade prostate cancer should be pursued in the first place.

What This Changes in Practice

Used within a comprehensive monitoring framework, MPS2-AS adds a layer of molecular precision that the field has been missing. Quarterly PSA trend monitoring, PHI scoring, annual non-contrast MRI, and a molecular urine test with a 99% negative predictive value together produce a substantially clearer picture of what is happening inside the prostate gland than any single tool provides in isolation. For a significant proportion of men on active surveillance, that combination could mean years of monitoring pass without a single biopsy being clinically justified.

The biopsy has been treated as the irreducible minimum of prostate cancer monitoring for decades, in part because nothing better was available. This study makes a credible case that it no longer has to occupy that position for most men in active surveillance. Whether that case is adopted into routine clinical practice will depend on how quickly the evidence diffuses into a field that has historically been slow to reduce procedural reliance even when the data supports doing so.

For men currently on active surveillance, the existence of this test is a reason to ask their urologist a direct question: given a 99% negative predictive value for high-grade disease, what is the clinical justification for scheduling a biopsy before this test has been used? That question has a reasonable answer in some cases. In many others, it may not.

The Intellectual Medicine podcast has covered the evidence on active surveillance, biopsy risk, and noninvasive monitoring in detail. For any man navigating a low-grade prostate cancer diagnosis, those conversations provide the clinical context that most surveillance appointments do not.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.